Trials / Completed
CompletedNCT03476655
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Johnson & Johnson Private Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the effectiveness (overall response rate \[ORR\] and time to progression \[TPP\]) of Ibrutinib therapy in participants with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib | No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed. |
Timeline
- Start date
- 2018-04-28
- Primary completion
- 2019-05-14
- Completion
- 2019-05-31
- First posted
- 2018-03-26
- Last updated
- 2025-02-03
Locations
8 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03476655. Inclusion in this directory is not an endorsement.